Drugs / Dex
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04831658 Background | Mar 2021 → Sep 2023 | primary central nervous system lymphoma | Mingzhi Zhang | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dex | “MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath” NCT04831658 ↗ |
| Route | Intrathecal | “MTX 12mg+Ara-C 50mg+Dex 5mg was injected into the CSF cytology-positive sheath, and intrathecal injection once per treatment cycle, a total of 6 times” NCT04831658 ↗ |